WO2003038052A3 - Nucleic acid-associated proteins - Google Patents

Nucleic acid-associated proteins Download PDF

Info

Publication number
WO2003038052A3
WO2003038052A3 PCT/US2002/034846 US0234846W WO03038052A3 WO 2003038052 A3 WO2003038052 A3 WO 2003038052A3 US 0234846 W US0234846 W US 0234846W WO 03038052 A3 WO03038052 A3 WO 03038052A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
naap
associated proteins
polynucleotides
agonists
Prior art date
Application number
PCT/US2002/034846
Other languages
French (fr)
Other versions
WO2003038052A2 (en
Inventor
Shanya D Becha
Original Assignee
Incyte Genomics Inc
Shanya D Becha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Shanya D Becha filed Critical Incyte Genomics Inc
Priority to AU2002359333A priority Critical patent/AU2002359333A1/en
Priority to CA002462660A priority patent/CA2462660A1/en
Priority to US10/491,472 priority patent/US20050186569A1/en
Priority to EP02793861A priority patent/EP1497315A2/en
Priority to JP2003540317A priority patent/JP2005508636A/en
Publication of WO2003038052A2 publication Critical patent/WO2003038052A2/en
Publication of WO2003038052A3 publication Critical patent/WO2003038052A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

Various embodiments of the invention provide human nucleic acid-associated proteins (NAAP) and polynucleotides which identify and encode NAAP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of NAAP.
PCT/US2002/034846 2001-10-29 2002-10-29 Nucleic acid-associated proteins WO2003038052A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002359333A AU2002359333A1 (en) 2001-10-29 2002-10-29 Nucleic acid-associated proteins
CA002462660A CA2462660A1 (en) 2001-10-29 2002-10-29 Nucleic acid-associated proteins
US10/491,472 US20050186569A1 (en) 2001-10-29 2002-10-29 Nucleic acid-associated proteins
EP02793861A EP1497315A2 (en) 2001-10-29 2002-10-29 Nucleic acid-associated proteins
JP2003540317A JP2005508636A (en) 2001-10-29 2002-10-29 Nucleic acid binding protein

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US34844201P 2001-10-29 2001-10-29
US60/348,442 2001-10-29
US33554401P 2001-11-01 2001-11-01
US60/335,544 2001-11-01
US33753501P 2001-11-05 2001-11-05
US60/337,535 2001-11-05
US34465001P 2001-11-09 2001-11-09
US60/344,650 2001-11-09
US33476201P 2001-11-15 2001-11-15
US60/334,762 2001-11-15

Publications (2)

Publication Number Publication Date
WO2003038052A2 WO2003038052A2 (en) 2003-05-08
WO2003038052A3 true WO2003038052A3 (en) 2004-11-11

Family

ID=27541124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/034846 WO2003038052A2 (en) 2001-10-29 2002-10-29 Nucleic acid-associated proteins

Country Status (5)

Country Link
EP (1) EP1497315A2 (en)
JP (1) JP2005508636A (en)
AU (1) AU2002359333A1 (en)
CA (1) CA2462660A1 (en)
WO (1) WO2003038052A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002310256A1 (en) * 2001-06-05 2002-12-16 Exelixis Inc. Ppp2cs as modifiers of the p53 pathway and methods of use
WO2006120019A2 (en) * 2005-05-13 2006-11-16 Centre National De La Recherche Scientifique Mcm9, a member of the mcm2-8 family and its use in pharmaceutical compositions
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PROTEIN [online] 1 November 1997 (1997-11-01), DIXON ET AL: "Identification of the complete coding sequence and genomic organization of the Treacher Collins syndrome gene", XP002903259, Database accession no. Q13428 *
GENOME RES., vol. 7, no. 3, 1997, pages 223 - 234 *
WISE ET AL: "TCOF1 gene encodes a putative nucleolar phosphoprotein that exhibits mutations in Treacher Collins syndrome throughout its coding region", PNAS USA, vol. 94, April 1997 (1997-04-01), pages 3110 - 3115, XP002903258 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug

Also Published As

Publication number Publication date
EP1497315A2 (en) 2005-01-19
WO2003038052A2 (en) 2003-05-08
JP2005508636A (en) 2005-04-07
AU2002359333A1 (en) 2003-05-12
CA2462660A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
WO2004087875A3 (en) Nucleic acid-associated proteins
WO2003052075A3 (en) Enzymes
WO2002063005A3 (en) Lipid-associated molecules
WO2003094848A3 (en) Nucleic acid-associated proteins
WO2003029437A3 (en) Secreted proteins
WO2002072794A3 (en) Immunoglobulin superfamily proteins
WO2003042357A3 (en) Enzymes
WO2003004615A3 (en) Secreted proteins
WO2002097060A3 (en) Carbohydrate-associated proteins
WO2002026950A3 (en) Transferases
WO2003054219A3 (en) Nucleic acid-associated proteins
WO2003076586A3 (en) Nucleic acid-associated proteins
WO2003060064A3 (en) Intracellular signaling molecules
WO2002101009A3 (en) Structural and cytoskeleton-associated proteins
WO2003038052A3 (en) Nucleic acid-associated proteins
WO2003010329A3 (en) Nucleic acid-associated proteins
WO2002066646A3 (en) Neurotransmission-associated proteins
WO2001083524A3 (en) Rna metabolism proteins
WO2003063769A3 (en) Vesicle-associated proteins
WO2003031939A3 (en) Protein modification and maintenance molecules
WO2002099115A3 (en) Nucleic acid-associated proteins
WO2003016549A3 (en) Nucleic-acid associated proteins
WO2003006618A3 (en) Nucleic acid-associated proteins
WO2003016506A3 (en) Secreted proteins
WO2003000864A8 (en) Nucleic acid-associated proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10491472

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2462660

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003540317

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002793861

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002793861

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002793861

Country of ref document: EP